NCT07482774 2026-03-19
TME-ESCC
Nanjing Medical University
Not yet recruiting
Clinical Trials
390 trialsNCT03301454 2026-03-18
E-DIS2
Centre Oscar Lambret
Phase 2 Terminated
NCT07457528 2026-03-11
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
NCT07205731 2026-03-05
SAFE ESO
University Hospital, Clermont-Ferrand
Phase 2 Recruiting
NCT07452601 2026-03-05
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT06452602 2026-02-27
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07039162 2026-02-27
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
China Medical University Hospital
Phase 2 Recruiting
NCT07437898 2026-02-27
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
The Affiliated Hospital of Putian University
Phase 2 Recruiting
NCT07403435 2026-02-11
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT05142709 2026-02-05
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Fudan University
Completed
NCT07385001 2026-02-03
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Tang-Du Hospital
Phase 1/2 Recruiting
NCT06952621 2026-01-30
TD-NEOE3V3
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT06828588 2026-01-29
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT07376876 2026-01-29
Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT07374003 2026-01-28
Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT07363629 2026-01-23
Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagectomy: A Randomized Controlled Trial
The First Hospital of Hebei Medical University
Phase NA Completed
NCT05978193 2026-01-22
SCR-ESCC-01
Shanghai Chest Hospital
Phase 2 Recruiting
NCT07359417 2026-01-22
ESCALATE
UMC Utrecht
Phase 1 Recruiting
NCT07353541 2026-01-20
PKU-ESCC-EF
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT07343869 2026-01-15
FEO
Société Française d'Endoscopie Digestive
Not yet recruiting
NCT04229459 2026-01-14
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Rabin Medical Center
Phase 2 Active not recruiting
NCT07339488 2026-01-14
ILDR-03
Shantou University Medical College
Phase 2 Active not recruiting
NCT03712566 2026-01-08
MASST
University Health Network, Toronto
Active not recruiting
NCT07317609 2026-01-05
Endosurgery-02
Shanghai Zhongshan Hospital
Phase 1 Recruiting
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT07290010 2025-12-17
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT07272291 2025-12-09
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07061704 2025-12-08
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 1/2 Recruiting
NCT07266493 2025-12-05
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT05427396 2025-12-03
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT05659251 2025-12-02
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07244978 2025-12-02
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT07246330 2025-11-24
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT05189730 2025-11-20
ETNT
Sichuan Cancer Hospital and Research Institute
Phase 2 Active not recruiting
NCT07236320 2025-11-19
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
Sichuan Cancer Hospital and Research Institute
Phase NA Completed
NCT06281886 2025-11-17
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06912074 2025-11-17
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT07086469 2025-11-17
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06192212 2025-10-02
PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Completed
NCT07201571 2025-10-01
A Retrospective Cohort Study of Patients Who Underwent Curative-intent Esophagectomy for ESCC at a Tertiary Referral Center in South Korea
Samsung Medical Center
Completed
NCT06333665 2025-09-30
PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Completed
NCT07181850 2025-09-18
pCR-ESCC
Nanjing Medical University
Completed
NCT06143748 2025-09-17
EC-CRT-006
Sun Yat-sen University
Phase 2 Active not recruiting
NCT07177794 2025-09-17
EC-CRT-008
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07152535 2025-09-03
PKU-ESCC
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT07152678 2025-09-03
BRIGHT-ESCC
National Taiwan University Hospital
Phase 2 Recruiting